Article
Court Narrows Literal Construction, But Catches Infringer In Equivalence Net
The U.S. Court of Appeals for the Federal Circuit reversed the district court's claim construction and holding of literal infringement, but affirmed its holding that Mayne's generic product infringed Abraxis' (formerly AstraZeneca's) three patents covering DIPRIVAN.
McDermott Will & Emery



